• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Galera Therapeutics Inc. (Amendment)

    2/14/24 10:14:42 AM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRTX alert in real time by email
    SC 13G/A 1 tm246006d2_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    Galera Therapeutics, Inc.

     

    (Name of Issuer)

     

    COMMON STOCK

     

    (Title of Class of Securities)

     

    36338D108

     

    (CUSIP Number)

     

    DECEMBER 31, 2023

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No.  28202V108 page 2 of 9

     

      1.

    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only).

     

    Sectoral Asset Management Inc

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) ¨
     
      3. SEC Use Only
     
      4.

    Citizenship or Place of Organization : Canada

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power     0
     
    6. Shared Voting Power   -0-
     
    7. Sole Dispositive Power            0
     
    8. Shared Dispositive Power   -0-
     

      9. Aggregate Amount Beneficially Owned by Each Reporting Person   0
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions).   ¨
     
      11. Percent of Class Represented by Amount in Row (9)           0%
     
      12. Type of Reporting Person (See Instructions)
        IA

     

     

     

     

    CUSIP No.  28202V108 page 3 of 9

     

      1.

    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only).

     

    Jérôme G. Pfund

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) ¨
     
      3. SEC Use Only
     
      4.

    Citizenship or Place of Organization : Swiss

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power     0
     
    6. Shared Voting Power   -0-
     
    7. Sole Dispositive Power            0
     
    8. Shared Dispositive Power   -0-
     

      9. Aggregate Amount Beneficially Owned by Each Reporting Person   0
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions).   ¨
     
      11. Percent of Class Represented by Amount in Row (9)           0%
     
      12. Type of Reporting Person (See Instructions)
        IN

     

     

     

     

    CUSIP No.  28202V108 page 4 of 9

     

      1.

    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only).

     

    Michael L. Sjöström

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) ¨
     
      3. SEC Use Only
     
      4.

    Citizenship or Place of Organization : Swiss

     

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power     0
     
    6. Shared Voting Power   -0-
     
    7. Sole Dispositive Power            0
     
    8. Shared Dispositive Power   -0-
     

      9. Aggregate Amount Beneficially Owned by Each Reporting Person   0
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions).   ¨
     
      11. Percent of Class Represented by Amount in Row (9)           0%
     
      12. Type of Reporting Person (See Instructions)
        IN

     

     

     

     

    CUSIP No.  28202V108 page 5 of 9

     

    Item 1. (a)

    Name of Issuer:  

     

    Galera Therapeutics Inc.

         
      (b)

    Address of Issuer's Principal Executive Offices:

     

    45 Liberty Blvd., Suite 230

    Malvern, Pennsylvania, 19355

    USA

     
    Item 2. (a)

    Name of Person(s) Filing:

     

    Sectoral Asset Management Inc.

    Jérôme G. Pfund
    Michael L. Sjöström

         
      (b)

    Address of Principal Business Office or, if none, Residence:

     

    The principal business address of each of the Reporting Persons is:
    1610-1010 Sherbrooke St. West, Montreal QC, H3A 2R7 Canada

         
      (c)

    Citizenship:

     

    Sectoral Asset Management Inc. is a Canadian corporation

    Jérôme G. Pfund is a Swiss citizen
    Michael L. Sjöström is a Swiss citizen

         
      (d)

    Title of Class of Securities:

     

    Common Stock

         
      (e)

    CUSIP Number:

     

    36338D108

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

      (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

     

     

     

    CUSIP No.  28202V108 page 6 of 9

     

      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
      (j) ¨  A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
      (k) ¨

    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ___________________

     

    Item 4. Ownership.

     

     

     

    Sectoral Asset Management Inc., in its capacity as an investment adviser, has the sole right to dispose of or vote the number of shares of common stock of the Issuer set forth in this filing. Jérôme G. Pfund holds majority of shares of Sectoral Asset Management Inc.

     

      (a)

    Amount beneficially owned:

     

    Sectoral Asset Management Inc.: 0 shares

    Jérôme G. Pfund: 0 shares

    Michael L. Sjöström: 0 shares

     

      (b)

    Percent of class:

     

    Sectoral Asset Management Inc.: 0%

    Jérôme G. Pfund: 0%

    Michael L. Sjöström: 0%

     

      (c) Number of shares as to which the person has:
         
        (i)

    Sole power to vote or to direct the vote:

    Sectoral Asset Management Inc.: 0 shares

    Jérôme G. Pfund: 0 shares

    Michael L. Sjöström: 0 shares

           
        (ii) Shared power to vote or to direct the vote:
    Not applicable
           
        (iii)

    Sole power to dispose or to direct the disposition of:

    Sectoral Asset Management Inc.: 0 shares

    Jérôme G. Pfund: 0 shares

    Michael L. Sjöström: 0 shares

           
        (iv) Shared power to dispose or to direct the disposition of:
    Not applicable.

     

     

     

     

     

    CUSIP No.  28202V108 page 7 of 9

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x

     
    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

     

     
    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

     

    Not applicable.

     
    Item 9.

    Notice of Dissolution of Group.

     

    Not applicable.

     
    Item 10. Certification.
       
     

    By signing below the undersigned each certifies that, to the best knowledge and belief of the undersigned, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No.  28202V108 page 8 of 9

     

    SIGNATURE

     

    After reasonable inquiry and to the best knowledge and belief of each of the undersigned, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated:  February 14, 2024 SECTORAL ASSET MANAGEMENT INC.
     

    /s/Marina Lalakin

      By:  Marina Lalakin
      Its:   Chief Compliance Officer
     
    Dated:  February 14, 2024 /s/Jérôme G. Pfund
      Jérôme G. Pfund

     

     

     

     

    CUSIP No.  28202V108 page 9 of 9

     

    Exhibit A

     

    AGREEMENT

     

    Each of the undersigned, pursuant to Rule 13d-1(k)(l) under the Securities Exchange Act of 1934, as amended, hereby agrees that only one statement containing the information required by Schedule 13G needs be filed with respect to the ownership by each of the undersigned of the shares of common stock of Galera Therapeutics, Inc. and that the Schedule 13G to which this Agreement is appended as Exhibit A is to be filed with the Securities and Exchange Commission on behalf of each of the undersigned on or about the date hereof.

     

    EXECUTED as a sealed instrument this 14th day of February 2024.

     

      SECTORAL ASSET MANAGEMENT INC.
       
      /s/Marina Lalakin
      By:  Marina Lalakin
      Its:   Chief Compliance Officer
       
      /s/Jérôme G. Pfund
      Jérôme G. Pfund

     

     

     

     

     

     

     

     

     

    Get the next $GRTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRTX

    DatePrice TargetRatingAnalyst
    8/10/2023$6.00 → $0.50Overweight → Neutral
    Piper Sandler
    12/20/2021$11.00 → $20.00Buy
    Citigroup
    12/15/2021$10.00Neutral → Buy
    HC Wainwright & Co.
    12/15/2021$15.00Neutral → Buy
    BTIG
    10/20/2021Buy → Neutral
    HC Wainwright & Co.
    10/19/2021$17.00 → $2.00Buy → Underperform
    BofA Securities
    10/19/2021Buy → Neutral
    BTIG Research
    More analyst ratings

    $GRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Galera downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Galera from Overweight to Neutral and set a new price target of $0.50 from $6.00 previously

      8/10/23 7:27:44 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup reiterated coverage on Galera Therapeutics with a new price target

      Citigroup reiterated coverage of Galera Therapeutics with a rating of Buy and set a new price target of $20.00 from $11.00 previously

      12/20/21 9:46:24 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Therapeutics upgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. upgraded Galera Therapeutics from Neutral to Buy and set a new price target of $10.00

      12/15/21 6:42:14 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chang Nancy T bought $499,979 worth of shares (7,644,932 units at $0.07) (SEC Form 4)

      4 - Galera Therapeutics, Inc. (0001563577) (Issuer)

      1/2/25 4:12:36 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schneid Yair bought $590,424 worth of shares (2,780,407 units at $0.21), increasing direct ownership by 35% to 10,823,610 units (SEC Form 4) (Amendment)

      4/A - Galera Therapeutics, Inc. (0001563577) (Issuer)

      5/1/24 5:02:03 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schneid Yair bought $166,417 worth of shares (932,402 units at $0.18), increasing direct ownership by 13% to 8,043,203 units (SEC Form 4)

      4 - Galera Therapeutics, Inc. (0001563577) (Issuer)

      2/26/24 4:06:04 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Accounting Officer Sussman Joel F.

      4 - Galera Therapeutics, Inc. (0001563577) (Issuer)

      5/5/25 4:19:43 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Sorensen Mel

      4 - Galera Therapeutics, Inc. (0001563577) (Issuer)

      5/5/25 4:17:46 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lokay Kevin G

      4 - Galera Therapeutics, Inc. (0001563577) (Issuer)

      2/26/25 4:57:11 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Galera Expands Commercial Leadership Team

      Company appoints leading sales, market access and operations executives with decades of experience successfully launching and commercializing new oncology products New Drug Application (NDA) for avasopasem is currently under priority review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee (PDUFA) target date of August 9, 2023 MALVERN, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the appointment of accomplished pharmace

      5/1/23 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Appoints Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer

      MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the appointment of Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer (CMO). Dr. Kennedy is a renowned Johns Hopkins-trained surgical oncologist and former Chief of Pancreatic and Hepatobiliary Surgery at Thomas Jefferson University with over 15 years' experience in clinical development and biopharma leadership. He will succeed Jon T. Holmlund, M.D., who will retire at the end of this yea

      9/1/22 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Appoints Mark J. Bachleda as Chief Commercial Officer and Jennifer Evans Stacey as Chief Legal and Compliance Officer

      MALVERN, Pa., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the appointment of Mark J. Bachleda, Pharm.D., M.B.A., as Chief Commercial Officer (CCO) and Jennifer Evans Stacey, Esq., as Chief Legal and Compliance Officer (CLCO) and Secretary. Both executives join Galera with over 25 years of leadership experience within the biopharmaceutical industry. "We are thrilled to welcome Mark and Jennifer to Galera at this critical point in the Company's growth," sa

      10/12/21 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRTX
    Financials

    Live finance-specific insights

    See more
    • Galera Therapeutics completes acquisition of Nova Pharmaceuticals

      Galera's development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer. Lead program is Phase 1/2 trial of Nova Pharmaceutical's Clinical Stage Nitric Oxide Synthase (NOS) Inhibitor on top of standard-of-care nab-paclitaxel and alpelisib in metaplastic breast cancer. Concurrent financing when added to Galera's existing cash balance, is anticipated to fund operations through data readout of its lead program and into 2026. Galera intends to leverage NCI grants, academic partnerships and the I-SPY 2 network for efficient and cost-effective clinical dataset expansion. MALVERN, Pa.

      12/31/24 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Adopts Limited Duration Stockholder Rights Agreement

      MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the "Board") has unanimously resolved to adopt a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company's common stock and the Rights Agreement is intended to enable all Galera stockholders to realize the full potential value of their investment in the comp

      5/3/24 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese

      The Company remains committed to its goal of bringing avasopasem to patients and intends to meet with FDA as soon as possible to discuss potential next steps Galera will take actions to extend its cash runway and continue enrolling its rucosopasem clinical trials Conference call tomorrow, August 10, 2023 at 8:30 a.m. ET MALVERN, Pa., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food an

      8/9/23 4:31:52 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Galera Therapeutics completes acquisition of Nova Pharmaceuticals

      Galera's development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer. Lead program is Phase 1/2 trial of Nova Pharmaceutical's Clinical Stage Nitric Oxide Synthase (NOS) Inhibitor on top of standard-of-care nab-paclitaxel and alpelisib in metaplastic breast cancer. Concurrent financing when added to Galera's existing cash balance, is anticipated to fund operations through data readout of its lead program and into 2026. Galera intends to leverage NCI grants, academic partnerships and the I-SPY 2 network for efficient and cost-effective clinical dataset expansion. MALVERN, Pa.

      12/31/24 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Announces Board Approval of Complete Liquidation and Dissolution

      MALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors has approved a Plan of Liquidation and Dissolution (Plan of Dissolution), which provides for the dissolution of the Company under Delaware law, and plans to seek stockholder approval of the Plan of Dissolution at a special meeting of stockholders to be held on or around October 17, 2024. If the Plan of Dissolution is approved by the Company's stockholders, the Company intends t

      8/14/24 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates

      MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the first quarter ended March 31, 2024, and provided recent corporate updates. "Our review of strategic options continues, as we strive to maximize value for our stockholders," said Mel Sorensen, M.D., Galera's President and CEO. "Potential options may include mergers, asset sales, divestiture, licensing arrangements, or other strategic transactions and may encompass a potential development path

      5/13/24 7:00:00 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRTX
    SEC Filings

    See more
    • SEC Form 8-K filed by Galera Therapeutics Inc.

      8-K - Galera Therapeutics, Inc. (0001563577) (Filer)

      4/2/25 5:05:17 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Galera Therapeutics Inc.

      10-K - Galera Therapeutics, Inc. (0001563577) (Filer)

      3/31/25 4:30:34 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Galera Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K/A - Galera Therapeutics, Inc. (0001563577) (Filer)

      3/24/25 6:13:44 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Galera Therapeutics Inc. (Amendment)

      SC 13G/A - Galera Therapeutics, Inc. (0001563577) (Subject)

      5/16/24 10:26:17 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Galera Therapeutics Inc.

      SC 13G - Galera Therapeutics, Inc. (0001563577) (Subject)

      5/16/24 10:25:53 AM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Galera Therapeutics Inc. (Amendment)

      SC 13G/A - Galera Therapeutics, Inc. (0001563577) (Subject)

      5/1/24 5:01:34 PM ET
      $GRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care